Literature DB >> 28094098

Altered balance of epidermis-related chemokines in epidermolysis bullosa.

Inkin Ujiie1, Yasuyuki Fujita2, Chihiro Nakayama1, Wakana Matsumura1, Shotaro Suzuki1, Satoru Shinkuma1, Toshifumi Nomura1, Riichiro Abe3, Hiroshi Shimizu4.   

Abstract

BACKGROUND: Epidermolysis bullosa (EB) is a congenital, refractory skin disease and there are no fundamental treatments. Recently, allogenic cell therapies are beginning to be applied as potential treatments, that are based on the concept that the allogenic cells can migrate into the skin and reconstitute the skin components. Although the mechanisms of cell migration into skin are not fully understood, chemokines are regarded as key factors in recruiting bone marrow-derived cells.
OBJECTIVES: Our study aims to elucidate the expression of chemokines in the EB patients.
METHODS: We determined the expression of wound-healing related chemokines in the sera, keratinocytes, and skin tissues of EB patients and compared them to those of healthy volunteers by enzyme-linked immunosorbent assays, quantitative reverse transcription PCR, and immunofluorescence staining.
RESULTS: The serum levels of CXCL12 and HMGB1 were found to be significantly elevated in the EB patients. Conversely, the serum levels of CCL21 were found to be lower in the EB patients than in healthy controls. In addition, the serum levels of CXCL12 tended to increase and the serum levels of CCL27 tended to decrease with an increase in the affected body surface areas. To detect the origin of the circulating chemokines, we performed immunofluorescence staining. CCL21, CCL27, HMGB1 and CXCL12 were stained more broadly in the EB patient tissues than those in the control tissues.
CONCLUSIONS: These results suggest that fluctuations in chemokine levels may contribute in a coordinated way to the wound-healing process and lend clues toward efficient cell therapies for EB.
Copyright © 2017 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CCL27; Chemokine; Epidermolysis bullosa; HMGB1; SDF-1

Mesh:

Substances:

Year:  2017        PMID: 28094098     DOI: 10.1016/j.jdermsci.2016.12.021

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  5 in total

1.  Pro-Inflammatory Chemokines and Cytokines Dominate the Blister Fluid Molecular Signature in Patients with Epidermolysis Bullosa and Affect Leukocyte and Stem Cell Migration.

Authors:  Vitali Alexeev; Julio Cesar Salas-Alanis; Francis Palisson; Lila Mukhtarzada; Giulio Fortuna; Jouni Uitto; Andrew South; Olga Igoucheva
Journal:  J Invest Dermatol       Date:  2017-07-20       Impact factor: 8.551

Review 2.  Keratins as an Inflammation Trigger Point in Epidermolysis Bullosa Simplex.

Authors:  Nadezhda A Evtushenko; Arkadii K Beilin; Anastasiya V Kosykh; Ekaterina A Vorotelyak; Nadya G Gurskaya
Journal:  Int J Mol Sci       Date:  2021-11-18       Impact factor: 5.923

3.  Immune Disregulation in Cutaneous Squamous Cell Carcinoma of Patients with Recessive Dystrophic Epidermolysis Bullosa: A Single Pilot Study.

Authors:  Angela Filoni; Gerolamo Cicco; Gerardo Cazzato; Anna Bosco; Lucia Lospalluti; Marco Tucci; Antonietta Cimmino; Caterina Foti; Andrea Marzullo; Domenico Bonamonte
Journal:  Life (Basel)       Date:  2022-01-30

Review 4.  A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy.

Authors:  Payal M Patel; Virginia A Jones; Christy T Behnam; Giovanni Di Zenzo; Kyle T Amber
Journal:  Antibodies (Basel)       Date:  2021-05-17

5.  Cutaneous T-cell-attracting chemokine as a novel biomarker for predicting prognosis of idiopathic pulmonary fibrosis: a prospective observational study.

Authors:  Takafumi Niwamoto; Tomohiro Handa; Yuko Murase; Yoshinari Nakatsuka; Kiminobu Tanizawa; Yoshio Taguchi; Hiromi Tomioka; Keisuke Tomii; Hideo Kita; Michihiro Uyama; Michiko Tsuchiya; Masahito Emura; Tetsuji Kawamura; Naoki Arai; Machiko Arita; Kazuko Uno; Akihiko Yoshizawa; Ryuji Uozumi; Izumi Yamaguchi; Fumihiko Matsuda; Kazuo Chin; Toyohiro Hirai
Journal:  Respir Res       Date:  2021-06-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.